Compared to the NS group and NGMC group, si-TCR GMCs transferred into KE4 tumor-bearing mice inhibited tumor growth specifically, while this effect was not observed in QG56 tumor-bearing mice (Fig. 3b, c, P < 0.05), indicating that administration of si-TCR gene-modified lymphocytes inhibited human tumor growth in NOD-SCID mice in a specific manner for MAGE-A4+HLA-A*2402+ KE4 tumors. This evidence concerns the gene HLA-A and neoplasm.